Abderrahman B, Jordan V
Endocrinology. 2018; 159(8):2980-2990.
PMID: 29931061
PMC: 6963694.
DOI: 10.1210/en.2018-00263.
Ghosh D, Lo J, Egbuta C
J Med Chem. 2015; 59(11):5131-48.
PMID: 26689671
PMC: 4915572.
DOI: 10.1021/acs.jmedchem.5b01281.
Pokhrel M, Ma E
Molecules. 2011; 16(12):9868-85.
PMID: 22124202
PMC: 6264551.
DOI: 10.3390/molecules16129868.
Chumsri S, Howes T, Bao T, Sabnis G, Brodie A
J Steroid Biochem Mol Biol. 2011; 125(1-2):13-22.
PMID: 21335088
PMC: 3104073.
DOI: 10.1016/j.jsbmb.2011.02.001.
Penning T, Lee S, Jin Y, Gutierrez A, Blair I
J Steroid Biochem Mol Biol. 2010; 121(3-5):546-55.
PMID: 20083198
PMC: 2894289.
DOI: 10.1016/j.jsbmb.2010.01.005.
Aromatase inhibitors: past, present and future in breast cancer therapy.
Dutta U, Pant K
Med Oncol. 2007; 25(2):113-24.
PMID: 17973095
DOI: 10.1007/s12032-007-9019-x.
Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
Jordan V, Brodie A
Steroids. 2006; 72(1):7-25.
PMID: 17169390
PMC: 2566956.
DOI: 10.1016/j.steroids.2006.10.009.
The role of aromasin in the hormonal therapy of breast cancer.
Dank M
Pathol Oncol Res. 2002; 8(2):87-92.
PMID: 12172571
DOI: 10.1007/BF03033716.
Design and synthesis of new steroidal inhibitors of estrogen synthase (aromatase).
Parish E, Li S, Rao Z
Lipids. 2000; 35(3):271-7.
PMID: 10783004
DOI: 10.1007/s11745-000-0523-0.
Risks and benefits of aromatase inhibitors in postmenopausal breast cancer.
Michaud L, Buzdar A
Drug Saf. 1999; 21(4):297-309.
PMID: 10514021
DOI: 10.2165/00002018-199921040-00005.
Comprehensive pharmacology and clinical efficacy of aromatase inhibitors.
Njar V, Brodie A
Drugs. 1999; 58(2):233-55.
PMID: 10473018
DOI: 10.2165/00003495-199958020-00003.
Inhibitors of aromatase prevent degradation of the enzyme in cultured human tumour cells.
Harada N, Hatano O
Br J Cancer. 1998; 77(4):567-72.
PMID: 9484813
PMC: 2149917.
DOI: 10.1038/bjc.1998.92.
Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.
Wiseman L, Goa K
Drugs Aging. 1996; 9(4):292-306.
PMID: 8894526
DOI: 10.2165/00002512-199609040-00006.
Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione.
Johannessen D, Adlercreutz H, Fotsis T, Lonning P
Br J Cancer. 1993; 68(2):393-8.
PMID: 8135918
PMC: 1968556.
DOI: 10.1038/bjc.1993.347.
Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer.
Bajetta E, Zilembo N, Buzzoni R, Noberasco C, Di Leo A, Bartoli C
Br J Cancer. 1994; 70(1):145-50.
PMID: 8018527
PMC: 2033308.
DOI: 10.1038/bjc.1994.265.
Second generation aromatase inhibitor--4-hydroxyandrostenedione.
Dowsett M, Coombes R
Breast Cancer Res Treat. 1994; 30(1):81-7.
PMID: 7949207
DOI: 10.1007/BF00682742.
First generation aromatase inhibitors--aminoglutethimide and testololactone.
COCCONI G
Breast Cancer Res Treat. 1994; 30(1):57-80.
PMID: 7949205
DOI: 10.1007/BF00682741.
Aromatase inhibitors--mechanisms of steroidal inhibitors.
Brueggemeier R
Breast Cancer Res Treat. 1994; 30(1):31-42.
PMID: 7949203
DOI: 10.1007/BF00682739.
Aromatase and its inhibitors in breast cancer treatment--overview and perspective.
Brodie A, Santen R
Breast Cancer Res Treat. 1994; 30(1):1-6.
PMID: 7949200
DOI: 10.1007/BF00682736.
Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.
Wiseman L, McTavish D
Drugs. 1993; 45(1):66-84.
PMID: 7680986
DOI: 10.2165/00003495-199345010-00007.